Genmab — Juli 2019

[Solsen]

Mon de kunne tænkes at ville oplyse Japan alene, hvis man spurgte.

[E_L]

Genmab updates prospectus with recent developments/ sales numbers https://www.sec.gov/Archives/edgar/data/1434265/000110465919040466/a19-3729_14fwp.htm

[Solsen]

Mon ikke emissionen kører igennem i aften.

[SP-1]

I think I read somewhere that the discounts of Q3 of 2018 the last one was and that from that point on the discounts where accounted every period. Can someone verify that?

[AaBforever]

Må da ikke håbe vi ender i minus...det vil være nedtur.

[Solsen]

Jeg hører rygter om $18,11 i emissionskurs

[lahn1]

Forkert chat, sorry

[SP-1]

@Solsen, it is mentioned on https://www.nasdaq.com/markets/ipos/company/genmab-as-777502-89779

[Jazzz]

Lahn1. Se i Biotek chatten

[Solsen]

$503 million in additional cash. Det er 1200 kr.

[Solsen]

Ingen rabat - dejligt. Men stadig for billigt. Lad os så se om US markedet værdsætter Genmab mere end CPH gør.

[peter12]

Ikke så meget nyt i j&j cc. De nævnte sc som vigtig da 50% af pts var outpatient. Den var også vigtig i andre indikationer.

[E_L]

Madeleine Armstrong
@ByMadeleineA
$JNJ execs asked about price for Darzalex subcutaneous formulation (if approved), and don't answer the question. But company believes Darzalex will be one of the main growth drivers for pharma division in future.

[nohope]

I´ve tried to get same kind of info from Jan Winkel, but he refused to answer.

[nohope]

Py-ha, der var vi godtnok heldige, den lukkede i plus

[Smadsen128]

Luk ???

[JKY_VH]

1219,50

[Hen]

1219,50

[JKY_VH]

Ja du fik ret Pensionisten:-)

[Smadsen128]

Tak Jky